Chapter 33. To market, to market - 2002

Annual Reports in Medicinal Chemistry

Volumn 38, Issue , 2003, Pages 347-374

  Boyer Joubert, Cècile ^a   Lorthiois, Edwige ^a   Moreau, François ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36148958707     PISSN: 00657743     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0065-7743(03)38034-0     Document Type: Article

References (163)

1. The collection of new therapeutic entities first launched in 2002 originated from the following sources: (a) CIPSLINE. Prous database; (b) Pharmaprojects; (c) IDdb, Current Drugs database; (d) Adis Business Intelligence R&D Insight, (e) IMS R&D Focus.
2. P. Bernardelli, B. Gaudillière and F. Vergne, Ann. Rep. Med. Chem., 37, 257 (2CKQ).
3. B. Gaudillière, P. Bernardelli and P. Berna, Ann. Rep. Med. Chem., 36, 293 (2001).
4. B. Gaudillière and P. Berna, Ann. Rep. Med. Chem., 35, 331 (2000).
5. B. Gaudillière, Ann. Rep. Med. Chem., 34, 317 (1999).
6. P. Galatsis, Ann. Rep. Med. Chem., 33 327 (1998).
7. Information Update, Drugs Fut., 25, 843 (2000).
8. S. Noble and K. L. Goa, Drugs, 58, 479 (1999).
9. M. Cullell-Young, N.E. Mealy, R. Castaner. L. Martin, M. del Fresno, L. Revel, M. Bayé, L.A. Sorbera, P. Cole, P.A. Leeson and J. Prous, Drugs Fut., 22, 685 (2002).
10. Anonymous, Molecule of the Month, Drugs News Perspect., 15, 527, (2002).
11. T. Ueda and T. Fukushima. Exp. Opin. Invest. Drugs, 5, 1639 (1996).
12. M. Ogawa, J. Cancer Res. Clin. Oncol. 125, 134 (1999).
13. Information update, Drugs Fut., 24, 1249 (1999).
14. M. Hanada, S. Mizuno, A. Fukushima, Y. Saito, T. Noguchi and T. Yamaoka, Jpn. J. Cancer Res., 89, 1229 (1998).
15. G.A. McMillin, W.E. Owen, T.L. Lambert, B.K. De, E.L. Frank, P.R. Bach, T.M. Annesley and W.L. Roberts, Clin. Chem., 48, 1580 (2002).
16. S.B. Ward, L. Sjostrom and M.R. Ujhelyi, Ther. Drug. Monit., 22, 599 (2000).
17. M. Eddleston, S. Rajapkase. S. Jayalath, L. Sjostrom, W. Santharaj. P.N. Thenabadu, M.H.R. Sheriff and D.A. Warrell, Lancet, 355,967 (2000).
18. Anonymous, Drug News Perspect., 15, 674 (2002).
19. P.J. Goodnick and J.M. Jerry, Expert Opin. Pharmacother., 3, 1773 (2002).
20. V. Ozdemir, J. Fourie and F. Ozdener, Curr. Opin. Invest. Drugs, 3, 113 (2002).
21. Information Update, Drugs Fut., 24, 1004 (1999).
22. Information Update, Drugs Fut., 25,961-963 (2000).
23. PCT Int. Appl. 9302055, (1993).
24. H. Iwasaki, S. Miyazaki, A. Tsuji, K. Yamaguchi and S. Goto, Chemotherapy, 41, 100 (1995).
25. K. Suzuki, M. Horiba, K. Ishikawa, S. Katoh, Y. Naida, M. Yanaoka and S. Andoh, Drugs, 49 (suppl 2), 376 (1995).
26. M. Matsumoto, K. Kojima, H. Nagano, S. Matsubara and T. Yokota, Antimicrob. Agents Chemother., 36, 1715 (1992).
27. M. Nakashima, T. Uematsu, M. Fukuchi, M. Nakano and K. Kosuge, Nippon Kagaku Ryoko Gakkai Zasshi, 43 (suppl 5). 115 (1995).
28. K. Kojima, T. Ito, K. Munemura, A. Kondo, M. Matsumoto. H. Nagano and S. Matsubara,Nippon Kagaku Ryoko Gakkai Zasshi, a(suppl5), 77 (1995).
29. C.M. Perry and T. Ibbotson. Drugs, 62.2221 (2002).
30. S.H. Sader and AC. Gales, Drugs, &j., 553 (2001)
31. T. Kumagai. S. Tamai, T. Abe, H. Matsunaga, K. Hayashi, I. Kishi, M. Shiro and Y. Nagao. J. Org. Chem., a,8145 (1998).
32. B. Chung, A.R. Suzuki and J.J. McGough, Exp. Opin. Emerging Drugs, 1,269 (2002).
33. G.M. Keating and D.P. Figgitt, Drugs, 62, 1899 (2002).
34. M.A. Stein, L.E. Arnold and J.M. Zito, Drugs, 62, 1905 (2002).
35. S.R. Pliszka, Exp. Opin. Invest. Drugs, 10, 1797 (2001).
36. Anonymous, Drug News Perspect., 13, 512 (2000).
37. A. Graul. J. Silvestre and J. Castaiier, Drugs Fut., 24, 246 (1999).
38. Information Update, Drugs Fut., 25, 304 (2000).
39. Information Update, Drugs Fut., 26, 291 (2001).
40. F. Machetti and A. Guarna, Expert Opin. Ther. Patents, 12, 201 (2002).
41. M.C. Michel, IDrugs, 5, 792 (2002).
42. K.M. J. Brands, R.B. Jobson. K.M. Conrad, J.M. Williams, B. Pipik, M. Cameron, A.J. Davies, P.G. Houghton, MS. Ashwood, I.F. Cottrell, R.A. Reamer, D.J. Kennedy, U.-H. Dolling and P.J. Reider, J. Org. Chem., 67, 4771 (2002).
43. A. Burke and M.D. Cunha, Drugs of Today, 3, 195 (2002).
44. R.N. Jones, J. Chemother, 13,363 (2001).
45. N.E. Mealy, R. Castaner, L. Martin, M. del Fresno, L. Revel, M. Bayes, M. Stringer, L. A. Sorbera, P. Cole, M. Cullell-Young, P.A. Leeson and J. Prous, Drugs Fut., 27,995 (2002).
46. L.A. Sorbera, L. Revel and R. Castafler, Drugs Fut., 26, 115 (2001).
47. A.L. McRae, Curr. Opin. Invest. Drugs, 3, 1225 (2002).
48. W.J. Burke, Expert. Opin. Invest. Drugs, 11, 1477 (2002).
49. I.W. Davies, J-J. Marcoux, E.G. Corley, M. Joumet, D-W Cai, M. Palucki, J. Wu, R.D. Larsen, K. Rossen, P.J. Pye, L. DiMichele, P. Dormer and P.J. Reider, J. Org. Chem., 65, 8415 (2000).
50. N. Chauret, J.A. Yergey, C. Brideau, R.W. Friesen, J. Mancini, D. Riendeau, J. Silva, A. Styhler, L.A. Trimble and D.A. Nicoll-Griffith, Bioorg. Med. Chem. Lett., 11, 1059 (2001).
51. L.A. Sorbera, R.M. Castaner, J. Silvestre and J. Castaner, Drugs Fut., 26, 346 (2001).
52. N.E. Mealy, L. Martin, R. Castalier, M. del Fresno, L. Revel, M. Bayes, L.A. Sorbera. P. Cole, P.A. Leeson and J. Prous, Drugs Fut., 27,403 (2002).
53. C.Q. Meng. Curr. Opin. Invest. Drugs, 3, 427 (2002).
54. C.Q. Meng, Curr. Opin. Invest. Drugs, 2,389 (2001).
55. R.M. Castarier, L.A. Sorbera and J. Castailer, Drugs Fut., 3,679 (2000).
56. J.R. Prous, Drugs Fut., 27,77 (2002).
57. Anonymous, Drug News Perspect., VI, 166 (2001).
58. H. Bays, Expert Opin. Investig. Drugs, 11, 1587 (2002).
59. H. Gylling and T.A. Miettinen, Curr. Opin. Invest. Drugs, 3. 1318 (2002).
60. M. Petitou, P. Duchaussoy, I. Lederman, J. Choay. P. Sinaÿ, J.C. Jacquinet and G. Torri, Carbohydr. Res., 167, 67 (1987).
61. J.M. Walenga, W.P. Teske, M.M. Samama, F.X. Frapaise, R.L. Bick and J. Fareed, Expert Opin. Invest. Drugs, 11,397 (2002).
62. J.C. Reverter, Drugs Today, 3, 185 (2002).
63. S.J. Keam and K.L. Goa, Drugs, 62,1673 (2002).
64. P. Cole and X. Rabasseda, Drugs of today, 38 (9) 615 (2002).
65. H.A.M. Mucke, Curr. Opin. Invest. Drugs, 3 (9) 1373 (2002).
66. S.E. Easthope and K.L. Goa, CNS Drugs, 15,969 (2001).
67. H.C. Diener, CNS Drugs, 15,977 (2001).
68. N.T. Mathew, CNS Drugs, 15,978 (2001).
69. Adis International Ltd, Drugs & Therapy Perspectives, u(2), 4 (2001).
70. A.E. Wakeling and J. Bowler, J. Steroid. Biochem. Mol. Biol., 43, 173 (1992).
71. A. Howell, C.K. Osborne, C. Morris and A.E. Wakeling, Cancer., 89, 817 (2000).
72. M. Levin, N. D’Souza and J. Castaner, Drugs Fut., 26,641 (2001).
73. K. Smolnikar, Drugs Today, 2, 783 (2001).
74. M. Levin, N. D’Souza and J. Castaner, Drugs Fut., 27,339 (2002).
75. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barbow, M.P. Healy, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, L. Henthorn and L. Richard, Bioorg. Med. Chem. Lett., 11,1911 (2001).
76. F. Ciardiello. Drugs, 60(suppl. 1), 25 (2000).
77. C.R. Culy and D. Faulds, Drugs, 62,2237 (2002).
78. T.E. Witzig, CA. White, G.A. Wiseman, L.I. Gordon, C. Emmanouilides, A. Raubitschek, N. Janakiraman, J. Gutheil, R.J. Schilder, S. Spies, D.H.S. Silverman, E. Parker and A.J. Grillo-López, J. Clin. Oncol., 17, 3793 (1999).
79. G.A. Wiseman, CA. White, R.B. Sparks, W.D. Erwin, D.A. Podoloff. D. Lamonica. N. L. Bartlett, J.A. Parker, W.L. Dunn, S.M. Spies, R. Belanger, T.E. Witzig and B.R. Leigh, Crit. Rev. Oncol. Hematol., 39, 181 (2001).
80. M.E. Juweid, J. Nucl. Med., 43, 1507 (2002).
81. ai. B.D. Cheson, Blood, 101,391 (2003).
82. H. Atarashi, A. Kuruma, T. Ino, H. Saitoh, T. Onodera, T. Ono and H. Hayakawa, Cardiovasc.Drugs Ther., z (Suppl. 2) 444 (1993).
83. S. Motomura, A. Hagihara. Y. Narumi and K. Hashimoto. J. Cardiovasc. Pharmacol., 31, 431.
84. A. Sugiyama, A. Takahara and K. Hashimoto. J. Cardiovasc. Pharmacol., 2, 70 (1999).
85. S louchi. H. Iwamura. M. Nishizaki. Havashi A., K. Senokuchi. K. Kobavashi, K. Sakaki. K. Hachiya,‘Y. lchioka and M. Kawamura, dhem. Pharm. Bull., 40, i 462 (1992).
86. N.H. Georgopapadakou, Expert Opin. Invest. Drugs, 11, 269 (2001).
87. R.A. Fromtling, Drugs Today, 3,245 (2002).
88. P.A. Hunter, Drug News Perspect., 14,440 (2001).
89. A.I. Graul, L.A. Sorbera and J.R. Prous, Drugs Today, 37, 703 (2001).
90. Abiogen Pharma SPA, Press release, 2002, June 12
91. F.J. Jary, V. Rihakova and A. Zabacova, Czech. Patent CSPIOI 18, (1982).
92. M. Mian, D. Benetti, R. Aloisi, S. Rosini and R. Fantozzi, Pharmacology, 2, 336 (1994).
93. R. Rizzoli and H. Fleish, Calcif. Tissue Int., 41, 202 (1987).
94. D. Gatti, E. Fracassi, F. Antoniazzi, E. Sartori, V. Braga, F. Corallo, D. Geraldi and S. Adami, Bone, 26(suppl. 3) Abst 33, (2000).
95. M. Al-Dhalimy, K. Overturf, M. Finegold and M. Grompe, Mol. Genetics & Metabolism, 75, 38 (2002).
96. M.G. Hall, M.F. Wilks, W.M. Provan, S. Eksborg and B. Lumholtz, Br. J. Clin. Pharm., 52, 169 (2001).
97. ,144, 179 (2000).
98. E. Barkaoui, D. Debray, D. Habes, H. Ogier and O. Bernard, Archives de Pediatric, 13, 540 (1999).
99. E. Holme and S. Lindstedt, J. Inherited Metabolic Disease, 21, 507 (1998).
100. E. Holme and S. Lindstedt, Clinics in Liver Disease, 4, 805 (2000).
101. S. Ahmad, J.H. Teckman and G.T. Lueder, Am. J. Ophtalmology, 134.266 (2002).
102. Anonymous, Drug News Perspect., 15,34 (2002).
103. A. Glasier, Expert. Opin. Invest. Drugs, 11, 1239 (2002).
104. A. Agarwal, IDrugs, $26 (2001).
105. G.T. Warner and B. Jarvis, Drugs, 62, 1345 (2002)
106. H. Yanagisawa, Y. Amemiya, T. Kanazaki, Y. Shimogi, K. Fujimoto, Y. Kitahara, T. Sada, M. Mizuno. M. Ikeda, S. Miyamoto, Y. Furukawa and H. Koike, J. Med. Chem., 39,323 (1996).
107. M. Mizuno, T. Sada and M. Ikeda, N. Fukuda, M. Miyamoto, H. Yanagisawa and H. Koike, Eur. J. Pharmacol. 285, 181 (1995).
108. J.J. Talley, S.R. Bertenshaw, D.L. Brown, J.S. Carter, M.J. Graneto, M.S. Kellogg, C.M. Koboldt, J. Yuan, Y.Y. Zhang and K. Seibert, J. Med. Chem., 43, 1661 (2000).
109. K.K. Jain. Expert Opin. Invest. Drugs, 9, 2717 (2000).
110. A.W. Gotta, IDrugs, 4, 939 (2001).
111. S.M. Cheer and K.L. Goa, Drugs, 61, 1133 (2001).
112. E.C. Huskisson, Drugs, a, 1143 (2001).
113. D. Carr, Drugs, 61, 1142 (2001).
114. Y. Todo, H. takagi, F. lino, K. Hayashi, M. Takata. H. Kuroda, K. Momonoi and H. Narita. Chem. Pharm. Bull., 42,2629 (1994).
115. Y. Fukuoka, Y. Ikeda, Y. Yamashiro, M. Takahata, Y. Todo and H. Narita, Antimicrob. Agents Chemother., 37, 384 (1993).
116. Information Update, Drugs Fut., 23, 917 (1998).
117. Information Update, Drugs Fut., 3,928 (1999).
118. A.P. Jonhson, Curr. Opin. Invest. Drugs, 1, 52 (2000).
119. K. Suzuki, Y. Horiba, K. Ishikawa. S. Katoh, Y. Naide, L. Yanaoka and S. Andoh, Drugs, 49(suppl. 2) 379 (1995).
120. H. Kobayashi, Drugs, 49(suppl. 2) 470 (1995).
121. M. Tanaka, T. Matsumoto, M. Sakumoto, K. Takahashi, T. saika, I. Kabayashi, and J. Kumazawa,. Antimicrob. Agents Chemother., 42, 579 (1998).
122. C. Paul, M. Graeber and A. Stuetz, Expert Opin. Invest. Drugs, $69 (2000).
123. R. Lawrence, DDT., 5, 114 (2001).
124. A. Graul and J. CastaAer, Drugs Fut., 23, 508 (1998).
125. Information Update, Drugs Fut., 25,539 (2000).
126. Information Update, Drugs Fut., 26, 508 (2001).
127. N.E. Mealy, L. Martin R. Castaner, L. Revel, M. Bayes, L.A. Sorbera, P. Cole, P.A. Leeson and J. Prous, Drugs Fut., 27,289 (2002).
128. R.E. Schopf, Curr. Opin. Invest. Drugs, 3, 720 (2002).
129. SMR Committee, Drug News Perspect., s,60 (2002).
130. M. Tracy and J. Castafier, Drugs Fut., 21,805 (1996).
131. K. Tougou, A. Nakamura, S. Watanabe, Y. Okuyama and A. Morino, Drug Metab. Dispos., S, 335 (1998).
132. M.P. Montanari, M. Mingoia and P.E. Varaldo, Antimicrob. Agents Chemother., 45, 3616 (2001)
133. Y. Tomii, M. Ozaki, M. Matsuda, T. Honmura, I. Nishimura, R. Yamaguchi, T. Adachi, Y. Okawa and T. Nishino, Arzmittel-Forshung, 46, 1169 (1996).
134. K. Kamata, A. Qgawa, T. Inoue, M. Ishihara, K. Ishimura, N. Sumi, H. Asaoka, Y. Shindo, T. Yoshida and S. Mitsuhashi, Antimicrob. Agents Chemother., 37, 793 (1993).
135. H. Ohbayashi, IDrugs, 2,910 (2002).
136. Information Update, Drugs Fut., 23, 1254 (1998).
137. Information Update, Drugs Fut., 24, 1287 (1999).
138. Information Update, Drugs Fut., 26, 1130 (2001).
139. P.T. Reid and J-M. Sallenave, Curr. Opin. Invest. Drugs, 2, 59 (2001).
140. Anonymous, Drug News Perspect., 15,371 (2002).
141. H. Ohbayashi, Expert Opin. Invest. Drugs, 11, 965 (2002).
142. H. Liu and B. Chen, Zhongguo Yiyao Gongye Zazhi, 2,152 (2001).
143. A.M. Ronn, Rev. Contemp. Pharmacother., lO,39 (1999).
144. R. Whelpton, A.T. Michael-Titus, R.P. Jandar, K. Abdillahi and M.F. Grahn, Photochemistry and Photobiology, 63, 885 (1996).
145. Q. Peng, J. Moan, L.W. Ma and J.M. Nesland, Cancer Research, 55,2620 (1995).
146. P. Norman, A. Graul, X. Rabasseda and J. Castaner, Drugs Fut., 25,693 (2000).
147. Information Update, Drugs Fut., 26, 718 (2001).
148. A.I. Graul, Drugs Fut., 27, 1181 (2002).
149. P.J. Barnes, Expert. Opin. Invest. Drugs, 10, 733 (2001).
150. T.T. Hansel and P.J. Barnes, Drugs of Today, 36,585 (2002).
151. E.M. Horn and R.J. Barst, Expert Opin. Investig. Drugs, 11.1615 (2002).
152. S.C. Chattaraj, Curr. Opin. Investig. Drugs, 3, 582 (2002).
153. L.A. Sorbera, X. Rabasseda and J. Castafler, Drugs Fut., 3, 364 (2001).
154. Annual review, Drugs Fut., 22, 102-103 (2002).
155. J.J. Talley, D.L. Brown, J.S. Carter, M.J. Graneto, CM. Koboldt, J.L. Masferrer, W.E. Perkins, R.S. Rogers, A.F. Shaffer, Y.Y. Zhang, B.S. Zweifel and K. Seibert, J. Med. Chem., 43, 775(2000).
156. L.A. Sorbera, P.A. Leeson, J. Castafier and R.M. Castaner, Drugs Fut., 26,133 (2001).
157. A.W. Gotta, Curr. Opin. Invest. Drugs, 3,240 (2002).
158. J. Fricke, J. Varkalis, S. Zwillich, R. Adler, E. Forester, D.P. Reeker and K.M. Verburg, Am. J. Ther. 9, 89 (2002).
159. Information update, Drugs Fut., 26, 318 (2001).
160. M.A. Hossain and M.A. Ghannoum, Expert. Opin. Invest. Drugs, 9,1797 (2000).
161. H.L. Hoftinan, E.J. Ernst and M.E. Klepser, Expert. Opin. Invest. Drugs, 9, 593 (2000).
162. H.L. Hoffman and R.C. Rathbun, Expert Opin. Invest. Drugs, 11,409 (2002).
163. P.H. Chandrasekar and Manavathu, Drugs of Today, 37,135 (2001).